your market intelligence analyst
Search Results
285 results
Your search is now limited to «GlaxoSmithKline» expert search.
Money Morning 08/20/2019 12:12
GlaxoSmithKline doesn't appear to be a top pharmaceutical stock to buy - at least not at first glance. Its shares have underperformed the global pharma sector by 60% over the past decade. But since Glaxo got a new CEO in 2017, the company has been on the path to a leaner, more focused company. Tags:. About Money Morning: Money Morning gives you access to a team of ten market experts with more than 250 years of combined investing experience – for free . 08/20/2019 07:20
Condition : Virus Diseases Interventions : Biological: Low dose formulation of RG SAM (CNE) vaccine (GSK3903133A); Biological: Medium dose formulation of RG SAM (CNE) vaccine (GSK3903133A); Biological: High dose formulation of RG SAM (CNE) vaccine (GSK3903133A); Drug: Saline Placebo; Biological: RabAvert Sponsor : GlaxoSmithKline Not yet recruiting.
More from 08/20/2019 04:58
Latest Research on “Global Argatroban Market 2019: Rising Industry Forecast Covering Growth Tendencies and Developments Until 2029.“Argatroban Market report delivers the clean elaborated structure of the market including each and every business-related important information of the market. The complete range of information is obtained through various sources and this obtained bulk of the information is arranged, processed, and represented by a group of specialists through the application of diff…
More from
Korean Biomedical Review 08/20/2019 04:50
GlaxoSmithKline (GSK) is solidifying its position in the local hair loss market with Avodart (ingredient: dutasteride), as the drug continues to show strong sales since receiving regulatory approval in 2009, the company said Tuesday.
More from Korean Biomedical Review:
FierceMedicalDevices 08/15/2019 17:03
In Martinez-Davis, GSK is picking up an exec with experience in one of its key focus areas: oncology.
More from FierceMedicalDevices:
Drug Store News 08/15/2019 14:54
GSK noted that Martinez-Davis has a track record of bringing new specialty treatments to market, a background that she will bring to the company as it focuses on an expanded pipeline and new oncology medicines.
More from Drug Store News: 08/14/2019 17:39
A federal judge overseeing hundreds lawsuits by women who claim the anti-nausea drug Zofran causes birth defects and that GlaxoSmithKline PLC failed to warn of its risks on Wednesday said the first trial nationally would take place in January.
More from
PMLiVE 08/13/2019 06:17
GlaxoSmithKline (GSK) has hired Merck KGaA’s Maya Martinez-Davis to replace Jack Bailey as the president of its US pharmaceuticals business.
More from PMLiVE:
pharmaphorum 08/13/2019 06:09
GlaxoSmithKline has poached Merck KGaA’s Maya Martinez-Davis to head up its US Pharmaceuticals division as it announces current president Jack Bailey will be stepping down at the end of the year.
More from pharmaphorum:
LocalTechWire 08/12/2019 12:52
GSK stops Ebola vaccine development, turns projects over to institute “GSK continues to evolve its business,” GSK said in a statement explaining the change.
More from LocalTechWire:
FiercePharmaManufacturing 08/12/2019 11:33
GlaxoSmithKline has seen plenty of changes across its executive ranks over the last couple of years as CEO Emma Walmsley took the helm, but they’re still coming.
More from FiercePharmaManufacturing:
ENDPOINTS 08/12/2019 10:42
GlaxoSmithKline said today that US pharmaceuticals president Jack Bailey “has decided to step down” at the end of the year.
More from ENDPOINTS:
FierceBiotech 08/09/2019 10:18
Currently, GSK is applying a panel of drugs with known efficacy and toxicity profiles, in order to compare TARA’s platform with other preclinical drug screening methods.
More from FierceBiotech:
GSK has granted exclusive technology license for its clinical-stage Ebola vaccines to the Sabin Vaccine Institute, a US-based nonprofit organisation that promotes global vaccine development.
More from Pharmaceutical Business Review: 08/06/2019 19:08
4] Under the agreements between GSK and Sabin, Sabin has exclusively licensed the technology for all three candidate vaccines and acquired certain patent rights specific to these vaccines.
More from

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors


Diagnostics and Therapeutics


Drugs - Brand Names

Drugs - Generic



Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices



Strategic Scenarios



On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 

  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications